Successful Treatment of Drug‐Resistant Cutaneous Leishmaniasis in Humans by Use of Imiquimod, an Immunomodulator
2001; Oxford University Press; Volume: 33; Issue: 11 Linguagem: Inglês
10.1086/324161
ISSN1537-6591
AutoresIracema Arevalo, Brian J. Ward, Richard L. Miller, Tze‐Chiang Meng, Enrique Najar, Eugenia Alvarez, Greg Matlashewski, Alejandro Llanos‐Cuentas,
Tópico(s)Synthesis and Biological Evaluation
ResumoTreatment failures for leishmaniasis with pentavalent antimonials, including meglumine antimonate, are increasingly common in many endemic areas. Imiquimod (Aldara; 3M Pharmaceuticals) is a novel immune response—activating compound, approved by the United States Food and Drug Administration, that is currently used to treat cervical warts and has been shown to activate macrophage killing of Leishmania species. Therefore, an open-label, prospective study was conducted of combined imiquimod plus meglumine antimonate therapy in 12 patients with cutaneous leishmaniasis who had previously not responded to meglumine antimonate therapy. All of the patients responded well to this combination therapy, and 90% were found to be cured at the 6-month follow-up period.
Referência(s)